Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents

Hiroaki Kariwa, Nobuhiro Fujii, Ikuo Takashima, Hiroaki Kariwa, Nobuhiro Fujii, Ikuo Takashima

Abstract

The efficacy of several povidone-iodine (PVP-I) products, a number of other chemical agents and various physical conditions were evaluated for their ability to inactivate the severe acute respiratory syndrome coronavirus (SARS-CoV). Treatment of SARS-CoV with PVP-I products for 2 min reduced the virus infectivity from 1.17 x 10(6) TCID(50)/ml to below the detectable level. The efficacy of 70% ethanol was equivalent to that of PVP-I products. Fixation of SARS-CoV-infected Vero E6 cells with a fixative including formalin, glutaraldehyde, methanol and acetone for 5 min or longer eliminated all infectivity. Heating the virus at 56 degrees C for 60 min or longer reduced the infectivity of the virus from 2.6 x 10(7) to undetectable levels. Irradiation with ultraviolet light at 134 microW/cm(2) for 15 min reduced the infectivity from 3.8 x 10(7) to 180 TCID(50)/ml; however, prolonged irradiation (60 min) failed to eliminate the remaining virus, leaving 18.8 TCID(50)/ml.

Figures

Fig. 1
Fig. 1
Kinetics of SARS-CoV inactivation by heating. Aliquots of SARS-CoV were heated in a 56°C water bath for the indicated times. The heated virus aliquots were serially diluted and inoculated onto monolayers of Vero E6 cells grown in 96-well plates. After incubation for 48 h, the cytopathic effect in the cells was observed and the infectivity was determined by the TCID50 method.
Fig. 2
Fig. 2
Kinetics of SARS-CoV inactivation by UV irradiation. Aliquots of SARS-CoV were irradiated with UV light for the indicated times. The irradiated virus aliquots were serially diluted and inoculated onto monolayers of Vero E6 cells grown in 96-well plates. After incubation for 48 h, the cytopathic effect in the cells was observed and the infectivity was determined by the TCID50 method.

References

    1. World Health Organization Acute respiratory syndrome, China. Wkly Epidemiol Rec. 2003;78:41.
    1. World Health Organization Acute respiratory syndrome China, Hong Kong Special Administrative Region of China, and Viet Nam. Wkly Epidemiol Rec. 2003;78:73–74.
    1. World Health Organization Severe acute respiratory syndrome (SARS) Wkly Epidemiol Rec. 2003;78:181–183.
    1. World Health Organization Severe acute respiratory syndrome (SARS): over 100 days into the outbreak. Wkly Epidemiol Rec. 2003;78:217–220.
    1. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM, Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ, National Microbiology Laboratory, Canadian Severe Acute Respiratory Syndrome Study Team Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005.
    1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
    1. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, De Risi J, Yang JY, Cox N, Hughes JM, Le Duc JW, Bellini WJ, Anderson LJ, SARS Working: Group A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966.
    1. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY, SARS Study. Group Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.
    1. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, De Risi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399.
    1. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan Y, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278.
    1. World Health Organization First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. Available from URL: .
    1. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–497.
    1. Yu IT, Li Y, Wong TW, Tam W, Chan AT, Lee JH, Leung DY, Ho T. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004;350:1731–1739.
    1. Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, Yam LY, Seto WH, Yuen KY, Peiris JS. Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis. 2004;10:294–299.
    1. Yam WC, Chan KH, Poon LL, Guan Y, Yuen KY, Seto WH, et al. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J Clin Microbiol. 2003;41:4521–4524.

Source: PubMed

3
Abonnere